Patient-friendly summary
If you read nothing else
Bottom line
Evidence supports a tailored, multidisciplinary plan—education, exercise, CBT, and a focused set of medications (duloxetine, milnacipran, pregabalin, amitriptyline)—chosen to fit each patient's main symptoms, while NSAIDs and acetaminophen are generally not recommended.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults with fibromyalgia, a condition reported to affect 1-5% of the population
Study Summary
This updated narrative review (evidence current to February 2024) summarizes pharmacologic and nonpharmacologic management of fibromyalgia, a chronic pain condition affecting an estimated 1-5% of the population and marked by widespread pain, fatigue, sleep disturbance, cognitive dysfunction, and mood changes. The authors emphasize a comprehensive, multidisciplinary approach beginning with patient education and combining exercise, psychotherapy (particularly CBT), and medication. Among drugs, the three FDA-approved options (duloxetine, milnacipran, pregabalin) plus amitriptyline show the most consistent symptom benefit, with drug choice tailored to a patient's predominant symptoms. NSAIDs and acetaminophen are generally not recommended, while emerging options such as low-dose naltrexone, cannabinoids, and NMDA-receptor antagonists show promise but require caution given limited evidence and adverse-effect potential.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Four medications carry the most consistent symptom benefit | Duloxetine, milnacipran, and pregabalin are the three FDA-approved drugs (accounting for roughly 70% of fibromyalgia prescriptions), and the tricyclic amitriptyline—though not FDA-approved—is recommended across clinical practice guidelines. Drug selection should target a patient's predominant symptoms. | High |
| Medication choice should be matched to symptom profile | Per a 2022 systematic review, amitriptyline had the greatest association with reduced sleep disturbance and fatigue, improved quality of life, and reduced FIQ scores by 30%; duloxetine showed the greatest improvement in pain and depression; milnacipran was less efficacious but improved pain and fatigue. Amitriptyline is preferred for comorbid sleep disturbance and duloxetine for comorbid depression, fatigue, and overall pain. | High |
| Nonpharmacologic care, especially CBT and exercise, is central and should start early | CBT is described as the most effective psychological therapy, superior for short-term pain-intensity reduction with a dose-response relationship for pain and depression. Moderate-quality evidence (2400 patients across 34 trials, 47 exercise interventions) showed aerobic exercise can decrease pain intensity, enhance physical function, and reduce fatigue severity, though long-term effects are not yet established. | High |
| NSAIDs and acetaminophen are generally not recommended | A 2017 Cochrane review found only a modest amount of very-low-quality evidence for NSAIDs, which are not recommended by EULAR or AWMF. Acetaminophen shows limited effect, attributed to a lack of action on central pain processing. | Medium |
| Pregabalin is the only antiepileptic with demonstrated moderate efficacy | A systematic review reported a number needed to treat (NNT) of 4-14 for 50% or greater pain reduction with pregabalin; other antiepileptics (clonazepam, phenytoin, valproic acid, carbamazepine, lamotrigine, oxcarbazepine, topiramate) showed little-to-no evidence for pain reduction. Pure mu-opioid agonists are contraindicated. | Medium |
| Several emerging therapies show promise but need more study | Low-dose naltrexone beat placebo over 12 weeks (mean difference 0.34 on a 1-10 pain scale); memantine reduced pain in a double-blind trial; low-dose IV ketamine gave short-term relief; cannabinoids (nabilone, dronabinol) had conflicting trial results. The authors urge caution due to limited evidence and potential adverse effects. | Medium |
Duloxetine, milnacipran, and pregabalin are the three FDA-approved drugs (accounting for roughly 70% of fibromyalgia prescriptions), and the tricyclic amitriptyline—though not FDA-approved—is recommended across clinical practice guidelines. Drug selection should target a patient's predominant symptoms.
Per a 2022 systematic review, amitriptyline had the greatest association with reduced sleep disturbance and fatigue, improved quality of life, and reduced FIQ scores by 30%; duloxetine showed the greatest improvement in pain and depression; milnacipran was less efficacious but improved pain and fatigue. Amitriptyline is preferred for comorbid sleep disturbance and duloxetine for comorbid depression, fatigue, and overall pain.
CBT is described as the most effective psychological therapy, superior for short-term pain-intensity reduction with a dose-response relationship for pain and depression. Moderate-quality evidence (2400 patients across 34 trials, 47 exercise interventions) showed aerobic exercise can decrease pain intensity, enhance physical function, and reduce fatigue severity, though long-term effects are not yet established.
A 2017 Cochrane review found only a modest amount of very-low-quality evidence for NSAIDs, which are not recommended by EULAR or AWMF. Acetaminophen shows limited effect, attributed to a lack of action on central pain processing.
A systematic review reported a number needed to treat (NNT) of 4-14 for 50% or greater pain reduction with pregabalin; other antiepileptics (clonazepam, phenytoin, valproic acid, carbamazepine, lamotrigine, oxcarbazepine, topiramate) showed little-to-no evidence for pain reduction. Pure mu-opioid agonists are contraindicated.
Low-dose naltrexone beat placebo over 12 weeks (mean difference 0.34 on a 1-10 pain scale); memantine reduced pain in a double-blind trial; low-dose IV ketamine gave short-term relief; cannabinoids (nabilone, dronabinol) had conflicting trial results. The authors urge caution due to limited evidence and potential adverse effects.
Strengths
- Up-to-date scope, with evidence cited as recent as February 2024
- Covers both pharmacologic and nonpharmacologic management in one practical clinical guide
- Translates evidence into symptom-matched, shared-decision-making guidance for clinicians
- Acknowledges weak or conflicting evidence for emerging therapies rather than overstating benefits
Limitations
- Narrative review without a stated systematic search strategy, inclusion/exclusion criteria, or risk-of-bias assessment, so selection bias is possible
- Much of the cited evidence is limited by small sample sizes and low study quality, especially for diet, supplements, and emerging drugs
- Long-term effectiveness of exercise and several interventions remains under study and unestablished
- Several mechanistic claims are described as theoretical or hypothesized rather than confirmed
- Some cited studies are restricted to women, limiting generalizability
Key Takeaways for Patients
What This Means for You
- 01Fibromyalgia is best managed with a combined plan, not a single pill—education, exercise, and talk therapy (especially CBT) are core parts of care and should start early.
- 02A small set of medications works best: duloxetine, milnacipran, and pregabalin (FDA-approved) plus amitriptyline. Your doctor should match the choice to your main symptoms—for example, amitriptyline for poor sleep, duloxetine for pain and low mood.
- 03Common painkillers like NSAIDs (e.g., ibuprofen) and acetaminophen are generally not recommended for fibromyalgia because evidence for them is weak.
- 04Newer options like low-dose naltrexone, cannabinoids, and ketamine show some promise but have limited evidence, so they should be used cautiously and in discussion with your clinician.
- 05No medication usually relieves all symptoms; expect modest benefits, and weigh them against side effects through shared decision-making with your clinician.